Considerations in selecting thrombolytic and antithrombotic therapy for treatment of myocardial infarction aboard navy ships at sea.
Serving medical needs aboard deployed Navy ships presents unique challenges. One of these is selecting agents for treating a myocardial infarction at sea. After comparing the currently available thrombolytic agents with respect to ease of administration, efficacy, storage requirements, cost, antigenicity, and other complications, we believe that streptokinase best meets the need for a thrombolytic agent aboard Navy ships. If associated antithrombotic therapy with heparin is considered necessary, then subcutaneous administration may often be preferred to intravenous use for reasons of cost and simplicity.
Balcom
T A
TA
Fleet Surgical Team One, Unit 25552, FPO AP 96601-6612, USA.
Allingham
T A
TA
D004356:Drug Storage; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008889:Military Personnel; D009203:Myocardial Infarction / Q000188:drug therapy*; D009326:Naval Medicine; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D014481:United States
D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase